2.88
0.18 (6.67%)
| Previous Close | 2.70 |
| Volume | 1,028,167 |
| Price / Book | 0.960 |
| 52 Weeks Range |
| Operating Margin (TTM) | -6,383.63% |
| Diluted EPS (TTM) | -1.23 |
| Quarterly Revenue Growth (YOY) | 5.20% |
| Total Debt/Equity (MRQ) | 1.34% |
| Current Ratio (MRQ) | 17.02 |
| Operating Cash Flow (TTM) | -53.72 M |
| Levered Free Cash Flow (TTM) | -87.14 M |
| Return on Assets (TTM) | -15.56% |
| Return on Equity (TTM) | -32.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Perspective Therapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -1.75 |
|
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| % Held by Insiders | 18.83% |
| % Held by Institutions | 61.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tcg Crossover Management, Llc | 30 Jun 2026 | 7,915,567 |
| Commodore Capital Lp | 30 Jun 2026 | 6,336,782 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 4,214,582 |
| Spruce Street Capital Lp | 30 Jun 2026 | 3,693,931 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |